Cognition Therapeutics (CGTX) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ProMIS Neurosciences (PMN) has outperformed Cognition Therapeutics (CGTX) over the past year, losing 35.8% versus a loss of 49.1%. Over five years, CGTX leads with a -92.5% price change compared with -95.9% for PMN. ProMIS Neurosciences is the larger company by market cap ($87.4 million vs $85.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | PMN |
|---|---|---|
| Share price | $0.8946 | $9.75 |
| Market cap | $85.07M | $87.39M |
| 1-day change | -0.07% | +6.50% |
| YTD return | -33.69% | +33.97% |
| 1-year return | -49.14% | -35.79% |
| 5-year return | -92.48% | -95.93% |
| EPS (TTM) | $-0.17 | $-11.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.05 | $27.40 |
| 52-week low | $0.55 | $6.27 |
| Distance from 52-week high | -56.36% | -64.43% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +272.23% | +337.25% |
| Average volume | 534.62K | 83.76K |
| Shares outstanding | 95.09M | 8.97M |
| Employees | 14 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMN has outperformed CGTX by 13.3 percentage points over the past year.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
CGTX vs PMN FAQ
Which is bigger, Cognition Therapeutics or ProMIS Neurosciences?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $87.39M compared with $85.07M for Cognition Therapeutics (CGTX).
Which stock has performed better over the past year, CGTX or PMN?
PMN returned -35.79% over the past 12 months, compared with -49.14% for CGTX (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and ProMIS Neurosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cognition Therapeutics and Biotechnology: Pharmaceutical Preparations for ProMIS Neurosciences.